RxDoctor Payments Data

Dixie Colgan

Family · Hampstead, MDNPI 1467859306

Payments from drug & device makers

$4,786in general payments, 2019–2025

Across 252 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$981
  • Novo Nordisk$919
  • AstraZeneca$769
  • Orexo US, Inc.$630
  • GSK$402
  • Lilly USA, LLC$209
  • plus $874 from 12 others

What the payments were for

  • Food & beverage$4,786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,786 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$110,723
Medicare patients
252
Services billed
1,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$49,141
EliquisApixaban37$36,779
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$25,738
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$16,257
FarxigaDapagliflozin Propanediol11$13,174
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,905
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$5,229
Tresiba Flextouch U-100Insulin Degludec11$5,153
Ziprasidone Hcl24$3,742
Atorvastatin Calcium218$2,894
Rosuvastatin Calcium153$2,147
Albuterol Sulfate HfaAlbuterol Sulfate78$2,091
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$1,750
Venlafaxine Hcl ErVenlafaxine Hcl11$1,673
Gabapentin95$1,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$919$49,14127 claims
AstraZenecaBreztri Aerosphere, Farxiga$769$38,91341 claims
PfizerEliquis$119$36,77937 claims
GSKTrelegy Ellipta$402$11,90519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Hampstead

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →